search

Active clinical trials for "Pancreatic Neoplasms"

Results 81-90 of 2501

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized...

Pancreas AdenocarcinomaResectable Pancreatic Cancer

The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.

Recruiting16 enrollment criteria

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source...

Pancreatic Cancer

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

Recruiting21 enrollment criteria

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Pancreatic Cancer

The purpose of this study is to evaluate the safety and clinical activity of tadalafil, pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma who have progressed after at least 1 prior chemotherapy regimen.

Recruiting25 enrollment criteria

U87 CART in Treatment of Advanced Pancreatic Cancer

Pancreatic Cancer

This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced Pancreatic Cancer.

Recruiting23 enrollment criteria

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic...

Pancreatic Neoplasms

It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer.

Recruiting20 enrollment criteria

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

MesotheliomaMesotheliomas Pleural16 more

TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.

Recruiting9 enrollment criteria

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With...

Advanced Solid TumorsDigestive System Neoplasms2 more

This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms

Recruiting29 enrollment criteria

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From...

Peritoneal CarcinomatosisPeritoneal Metastases6 more

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.

Recruiting20 enrollment criteria

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome...

Carcinoid SyndromeCarcinoid7 more

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

Recruiting12 enrollment criteria

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination...

Pancreatic Cancer

The goal of this Single Arm Phase Ib clinical trial is to test standard of care chemotherapy and anti PD1 and IL1b to evaluate the safety and preliminary toxicity of this quadruplet regimen prior to resection in patients with pancreatic cancer. The main objectives it aims to answer are to: Determine the recommended Phase II dose regimen of canakinumab and tislelizumab in combination with gemcitabine and nab-paclitaxel in patients with localized pancreatic ductal adenocarcinoma. Estimate the proportion of patients who proceed to surgical resection. Determine the safety and tolerability of canakimumab in combination with tislelizumab, nab-paclitaxel and gemcitabine Assess the preliminary clinical anti-tumor activity of canakimumab in combination with tislelizumab, nab-paclitaxel and gemcitabine Assess whether therapy has any impact on surgical options Participants will have labs drawn, CT scans, and a treatment administered consisting of: Gemcitabine Nab-paclitaxel Canakinumab Tislelizumab

Recruiting36 enrollment criteria
1...8910...251

Need Help? Contact our team!


We'll reach out to this number within 24 hrs